Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Unusual ALS Case Highlights Variable Onset
24 January 2012. Like many neurodegenerative conditions, amyotrophic lateral sclerosis is a disease of aging. Thus, it was unusual when a young man of 19 visited Guy Rouleau’s practice at the University of Montréal, Canada. The teen turned out to have a novel mutation in the ALS gene Fused in Sarcoma (FUS). His case corroborates previous work suggesting FUS-based ALS can hit the young, and it highlights the extraordinary variability in the disease. Rouleau was senior author on the study with first author Veronique Belzil, also at the University of Montréal.

ALS symptoms typically appear in one’s 40s and 50s, although juvenile cases in people younger than 25 do occur. In addition to the early onset, the young man in the case study was unusual in that his weakness and muscle atrophy affected mostly his right arm, shoulder and neck. However, he did have mild weakness elsewhere, convincing Rouleau that ALS was the correct diagnosis.

The team sequenced three likely candidate ALS genes: FUS, superoxide dismutase 1 (SOD1), and TAR DNA Binding Protein 43 (TDP-43). They discovered a single base pair deletion near the end of the FUS gene, causing a frameshift that swapped the final 32 correct codons for 33 new, incorrect ones. This genetic defect joins several others found previously in the carboxyl terminus of FUS, confirming the importance of that region for the protein’s function (see ARF related news story on Dormann et al., 2010).

The young man’s mother, the team found, also carried the FUS mutation, yet had no ALS symptoms at 47. Several mutations in FUS and other ALS genes have a wide range of onset (see table), causing disease in individuals as young as 13 or as old as 72 (see ARF related news story on Yan et al., 2010).

“The major message here is that there is a good deal of heterogeneity in all forms of ALS,” wrote Richard Bedlack of the Duke ALS Clinic in Durham, North Carolina, in an email to ARF (see full comment below). “This includes variability in penetrance, age and site of onset, co-morbidities (for example dementia) and progression rate.” Bedlack did not participate in the current case study.

ALS Genes Associated With Juvenile Onset

Gene Age of Onset Reference
ALSIN 3-20 Hadano et al., 2001; Yang et al., 2001
SETX <25 Chen et al., 2004
UBQLN2 16-71 Deng et al., 2011
SIGMAR 1-2 Al-Saif et al., 2011
FUS 20, 65 DeJesus-Hernandez et al., 2010
17-22 Bäumer et al., 2010
13, 21 Huang et al., 2010
13-72 Yan et al., 2010
20 Belzil et al., 2011
19 Belzil et al., 2012

The variable onset, Rouleau said, could be the result of genetic or environmental factors. In the man in Montréal, the researchers used further sequencing to eliminate one potential genetic risk factor, that is, lengthy repeats in the ataxin 2 gene (see ARF related news story on Elden et al., 2010). In his case, they suspect that environmental toxins could have hastened disease. The young man had worked on farms around organophosphate fertilizers linked to neurodegeneration, as well as around heavy metals during a job in toxic waste recycling and training as a welder.

“I think we now need to focus hard on this variability... Mother Nature is trying to tell us something here!” Bedlack wrote. “We could, for example, use new tools such as whole genome microarray to compare fast and slow progressors.”—Amber Dance.

Reference:
Belzil VV, Langlais JS, Daoud H, Dion PA, Brais B, Rouleau GA. Novel FUS deletion in a patient with juvenile amyotrophic lateral sclerosis. Arch Neurol. 2012 Jan 16. Abstract

 
Comments on News and Primary Papers
  Comment by:  Richard Bedlack
Submitted 24 January 2012  |  Permalink Posted 24 January 2012

In my opinion the major message here is that there is a good deal of heterogeneity in all forms of ALS, even in specific subtypes of familial ALS such as this. This includes variability in penetrance, age and site of onset, comorbidities (for example dementia) and rate of progression. There are several possible reasons for this type of variability, including the specific site of each person's mutation within a given gene, possible modifier genes (for example kifap 3), and also possible environmental influences (for example exercise, lipid status).

Personally I think we now need to focus hard on this variability between patients....mother nature is trying to tell us something here! We could for example use new tools such as whole-genome microarray to compare fast and slow progressors. If we can understand this variability we may be able to shift patients' systems over to a more favorable phenotype even if we don't fully understand why it works.

View all comments by Richard Bedlack

  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad